spinal cord News
-
Spinal Cord Injury (SCI) Awareness Month
September is National Spinal Cord Injury (SCI) Awareness Month. With over 17,000 new spinal cord injuries taking place every year in the U.S., there is a significant need to call attention to the severity of spinal cord injuries and for continued research to aid in finding a cure. To sustain an SCI is extremely traumatic for the individual, and it also takes a toll on their family, friends, ...
-
Meagan Medical Inc. Announces Issuance of a Key U.S. Patent for a Disruptive Chronic Pain Treatment using Spinal Cord Stimulation
Patent provides protection for High Frequency Spinal Cord Stimulation with Beat Technology Vancouver, Washington – March 20, 2015 – Meagan Medical Inc., a clinical research and medical device development company focused on investigating and developing optimal ways of managing and controlling pain, announced today the issuance of a key patent related to a unique ...
-
FARCO-PHARMA supports “Protect the vulnerable“
Europe-wide aid project for the protection of people with paraplegia Cologne, 28/05/2020 – COVID-19 can be particularly dangerous for people with severe spinal cord injuries. That is why FARCO-PHARMA supports the European Spinal Cord Injury Federation (ESCIF) and the Association of Paraplegics in Germany e.V. (FGQ) with the supply of free protective masks for the caregivers of this ...
-
Design freeze of ABLE Exoskeleton
After creating 7 iterative versions of the exoskeleton prototype that have been tested in individuals with spinal cord injury to validate product-market fit and receive early feedback in order to adapt, change and redesign the device, we have frozen the design of the ABLE Exoskeleton. The final design will be revealed at RehabWeek, the leading conference in rehabilitation technology, in Rotterdam ...
-
Saluda Medical Announces $125M Equity Financing Led by Redmile Group LLC and New Investors Fidelity Management & Research Company LLC and T. Rowe Price Associates, Inc.
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, earlier this quarter finalized US $125 million in equity financing, led by existing investor Redmile Group LLC as well as ...
-
What do clinical experts say about the ABLE Exoskeleton?
We interviewed Prof. Dr. Ing. Rüdiger Rupp, a key opinion leader in the field of rehabilitation technology with more than 25 years of clinical experience, to talk about rehabilitation, exoskeleton technology, clinical trials and many more. Prof. Dr. Ing. Rüdiger Rupp is the Head of Experimental Neurorehabilitation at the Heidelberg University Hospital in Germany. Throughout his ...
-
The future of rehabilitation
Congratulations to the ONWARD team for the incredible progress they are making in the field of neuroengineering! In recent days, numerous media have reported the news of a great advance for science, and especially for all those people with spinal cord injury and their medical and caregiver teams. The ONWARD team has developed an epidural electrical stimulation system using electrodes placed ...
-
New Clinic in Turkey with Exoskeleton
There is an opportunity to undergo rehabilitation course with ExoAtlet for all patients who require rehabilitation from the effects of stroke, spinal cord injury, multiple sclerosis, cerebral palsy in Turkey. We have partnered with Romatem – the first and only medical center in Turkey specializing in the field of physiotherapy and rehabilitation. For more than 12 years the center have been ...
By ExoAtlet
-
Coloplast and the World Diabetes Foundation prevent amputations in India
Coloplast"s donation programme Access to Healthcare just signed a contract with the World Diabetes Foundation (WDF) about a new healthcare project in India. The project aims to improve the treatment of diabetic wounds. "Every single day, 110 Indians have a foot or part of their leg amputated due to diabetic foot ulcers, and an unknown number die before they are even diagnosed," says Per Ole ...
-
Saluda Medical Announces Executive Leadership Changes
Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann as President & Chief Executive Officer. Mr. Schuermann joined Saluda Medical as President in June 2020. The company also announced that founder and CEO John ...
-
Nalu Medical Announces Scientific Presentations at 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting
Nalu Medical, Inc. (“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all selected for oral ...
-
Publication of Two-Year EVOKE Double-Blind Randomized Controlled Trial Results in JAMA Neurology Demonstrate Sustained Superiority of Evoke® Closed-Loop over Open-Loop Spinal Cord Stimulation
Saluda Medical Pty Limited (“Saluda Medical”), a global company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced long-term results of its double-blind Level 1 EVOKE randomized controlled trial (RCT) published online in ...
-
Clinical investigations
We performed 2 clinical trials in leading neurorehabilitation hospitals in Germany and Spain proving safety, feasibility and usability of the exoskeleton in a clinical setting, and showing significant improvements in clinical outcomes and benefits in rehabilitation. A Multicentric Clinical investigation in Institut Guttmann (Spain) and Heidelberg University Hospital (Germany), leading European ...
-
Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro`s 10 kHz Therapy
SENZA-PDN Randomized Controlled Trial Results Demonstrate Significant and Sustained Outcomes with 10 kHz Therapy at 18-Months Follow-Up. SENZA-NSRBP Randomized Controlled Trial Results Show Profound Improvements in Non-Surgical Refractory Back Pain Patients Receiving 10 kHz Therapy Relative to Conventional Medical Management at 12-Months Follow-Up. Both SENZA-PDN and SENZA-NSRBP Studies ...
By Nevro Corp.
-
Saluda Medical Announces Robust Scientific Presence at 2022 International Neuromodulation Society (INS) World Congress
Key data highlights with the Evoke® System to include holistic composite treatment outcomes for disrupting the chronic pain cycle; opioid-sparing effects of therapy; real-world results; and cost-effectiveness compared to open-loop stimulation. Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an ...
-
Nalu Micro-Implantable Pulse Generator Receives Expanded FDA Label for Service Life of 18 Years
Nalu Medical, Inc. (“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for the treatment of chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), in July 2020 received clearance from the U.S. Food and Drug Administration (FDA) of an expanded label for its micro-Implantable Pulse Generator (mIPG) to an ...
-
Saluda Medical Announces Highlights from 2021 North American Neuromodulation Society (NANS) Meeting
Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS 2021) Virtual Meeting, including real-world European commercial results and sub-analyses of 24-month and 12-month clinical data from the ...
-
Nalu Medical Named Best MedTech Company and Medical Device in Field of Neurology
Nalu Medical is pleased to announce its flagship micro-Implantable Pulse Generator (mIPG™) was selected as the 2021 winner of the MedTech Visionaries Award for Best MedTech Company and Best Medical Device in the field of neurology. The MedTech Visionaries Awards honor organizations that apply science and technology to real-world problems to advance MedTech solutions for businesses and ...
-
Saluda Medical Announces Publication of 24-Month Spinal Cord Stimulation Results with the Evoke® System
Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy ~83% of patients reduced or eliminated opioid use Need for patient re-programming visits nearly eliminated after 12 months Represents the first peer reviewed SCS study to show responder and high responder rate improvement over time Saluda Medical Pty Limited ...
-
Saluda Medical Receives FDA Approval for the Evoke® Spinal Cord Stimulation System to Treat Chronic Intractable Pain
Transformative closed-loop technology senses the spinal cord’s response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment Long-term results published in two premier clinical journals show clinically meaningful improvements in pain relief, physical and emotional functioning, sleep quality, and health-related quality of life Saluda Medical Pty ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you